June 2008

TABLE OF CONTENTS

The Big Three ““ Employees, Managers & Customers
Derrek G. Hennecke, MBA, continues with part 5 of his 7-part series chronicling the challenges, issues, and more importantly, the opportunities he faced throughout his successful Management Buy-Out. 

Biochemical Bitter Blocking for New Drug Formulations

F. Raymond Salemme, PhD, discusses his company’s bitter-blocker discovery process focused on finding novel blockers of bitter and other aversive tastes to make medicines and over-the-counter products more palatable.

 

Castable Edible Pharmaceutical Films

Ming J. Chen, PhD; Gloria Tirol, Charles Bass, Caroline Corniello, MS; Gavin Watson, and Ivonne Sanchez investigate drug delivery via fast-dissolving and extended-release edible films for dissolution time, release profiles, and film strength.

 

Current Challenges in Drug Delivery

Frost & Sullivan Analyst Daniel Ruppar talks about how understanding both market and end-user factors can provide companies with a clearer picture of the true commercial opportunity for a delivery technology-enabled drug in the marketplace.

 

Rexam Pharma: Fully Focused on Creating Customer Value

Drug Delivery Executive: Marc Hämel, Rexam Pharma’s Managing Director, discusses his organization’s strategic direction in becoming a leader in ophthalmic, injection, and inhalation products and devices.

 

Outsourcing Formulation Development: Strategic Partners in Today’s Development Climate

Contributor Cindy H. Dubin talks with leaders in the contract service community to find out what trends are shaping the CRO-Specialty Pharma relationship and how that partnership can be maximized.

 

Cyclobenzaprine ER: Development of the First Once-Daily Muscle Relaxant

Troy M. Harmon, MS, MBA, provides an overview of the development and commercialization of cyclobenzaprine ER as an example of applying a drug delivery technology to successfully enter a therapeutic market and improve patient’s lives.

 

InSite Vision: Multiple Products, Minimal Risk

Executive Summary: Dr. S. Kumar Chandrasekaran, Chairman & CEO of InSite Vision, discusses the role of drug delivery technology in transforming the company in a low-risk manner from an R&D organization to a sustainable, multiple products company.

 

DEPARTMENTS

 

Market News & Trends

 

Excipient Update

Polyvinylpyrrolidone (PVP) ““ One of the Most Widely Used Excipients in Pharmaceuticals: An Overview

 

Technology Showcase

 

Facts & Figures

 

External Delivery

Who’s the Boss?                                 

COVER

FEATURES